A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study of the Efficacy, Safety, and Tolerability of TAK-536 in Patients With Mild to Moderate Uncomplicated Essential Hypertension.
Phase of Trial: Phase II
Latest Information Update: 01 Jan 2017
At a glance
- Drugs Azilsartan (Primary) ; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 24 Jan 2009 Planned number of patients (555) added as reported by ClinicalTrials.gov.
- 15 Oct 2008 New trial record.